[Clinical Update] Aptabio hits primary endpoint in Phase 2 trial of APB-? (aptamer-based drug)
Predicted impact: Medium
Phase 2 primary endpoint result for a biotech; a prior item already reported the same milestone, so level lowered.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.